Drug intelligence / Profile preview

crizotinib + erlotinib + gefitinib + icotinib + zoledronate

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This appears to be a combination of five different drugs: crizotinib (an ALK inhibitor), erlotinib (an EGFR inhibitor), gefitinib (an EGFR inhibitor), icotinib (an EGFR inhibitor), and zoledronate (a bisphosphonate). Based on the available information, this specific combination is not a standard therapeutic regimen. Each drug has its own mechanism of action and approved indications. Erlotinib specifically is a tyrosine kinase inhibitor that blocks EGFR activity and is used to treat non-small cell lung cancer with specific EGFR mutations and pancreatic cancer.

Targets

ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)

Beyond the preview

Go deeper on crizotinib + erlotinib + gefitinib + icotinib + zoledronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on crizotinib + erlotinib + gefitinib + icotinib + zoledronate.

Explore the full profile